DIRS.INFO The most relevant business & tech news

☆ I.V.F. Threats in Alabama Drive Clinics to Ship Out Embryos
▼ + stars: | 2024-08-12 | by ( Azeen Ghorayshi | Sarah Kliff | ) www.nytimes.com time to read: +1 min

An emerging movement against in vitro fertilization is driving some doctors and patients in red states to move or destroy frozen embryos. The embryo migration is most striking in Alabama, where the State Supreme Court ruled in February that embryos were “unborn children.” Since then, at least four of Alabama’s seven fertility clinics have hired biotech companies to move the cells elsewhere. A fifth clinic is working with a doctor in New York to discard embryos because of concerns about the legality of doing so in Alabama. Since the Supreme Court’s 2022 decision to overturn Roe v. Wade, 14 states have passed total or near total abortion bans. And the Southern Baptists, the country’s largest Protestant denomination, voted in June to oppose I.V.F., calling for the protection of “frozen embryonic human beings.”

Persons: Roe, Wade Organizations: Baptists, I.V.F Locations: Alabama, New York

☆ I'm a scientist who moved to Lithuania from the US. I am less stressed and my work-life balance is so much better that I don't consider moving back any time soon.
▼ + stars: | 2024-08-10 | by ( Jessica Orwig | ) www.businessinsider.com time to read: +6 min

Read previewThis as-told-to essay is based on a conversation with Stephen Knox Jones Jr., a 37-year-old scientist who lives in Vilnius, Lithuania. Here, people recognize the value of having time away from work for well-being — and now I don't feel guilty anymore when I take time off. Jones Jr. thinks the quality of his research is better because he's less stressed and has more head space to dedicate to his work. That's why I think the quality of my research is better in Lithuania than it might be in the US. Jones Jr.'s quality of research is important to him because of his strong desire to contribute to humanity's advancement.

Persons: —, Stephen Knox Jones Jr, It's, there's, that's, I've, Jones, it's, Stephen, Jessica Orwig Organizations: Service, Business, Molecular Biology Laboratories, Jobs Locations: Vilnius, Lithuania, New Hampshire, Rhode Island, Texas, After Texas, Europe, jorwig@businessinsider.com

If approved, it would have been the first new treatment for PTSD in more than two decades. Lykos Therapeutics had asked the FDA to approve the drug as part of a treatment regimen, given alongside talk therapy. Lykos Therapeutics had asked the FDA to approve the drug as part of a treatment regimen, given alongside talk therapy. Lykos added that the agency expressed concerns similar to those raised during the advisory committee meeting in June. Davis Institute for Psychedelics and Neurotherapeutics, said he doesn’t think the FDA decision will hinder the development of psychedelics for mental health disorders, including PTSD.

Persons: “, ”, Holly Fernandez Lynch, Lykos, Amy Emerson, Sarah Silbiger, David Olson, Olson, ” Olson, Brian Barnett, ” Barnett, Joe Biden, Biden, Robert Califf, ” Lynch, psychedelics, David Rind Organizations: Drug Administration, Therapeutics, FDA, Lykos Therapeutics, University of Pennsylvania, Davis Institute for Psychedelics, Cleveland Clinic, Clinical Locations: U.S, White Oak, Md, Ohio

☆ Antiaging enthusiasts are getting $16,500 injections to make their knees young again
▼ + stars: | 2024-08-09 | by ( ) www.businessinsider.com time to read: +11 min

For now, here's what we know — and what we don't know — about stem-cell therapy for knees. Bryan Johnson flew to the Bahamas to get MSC stem cells injected into his knees, hips, and shoulders — for about $16,500 per joint. Plus, even Sampson warns that young donor stem cells should not be seen as a quick fix or a panacea. Done with proper medical oversight, some studies have found no adverse effects from stem-cell treatments for various conditions. Botched stem-cell treatments can cause infection, blindness, and excessive cell growth, which can trigger the formation of tumors.

Persons: —, Bryan Johnson, Johnson, hasn't, Josh DeAngelis, Rasul Chaudhry, Chaudhry, Steven Sampson, Chaundhry, Sampson, Peyton Manning, Patrick Smith, George Kittle, Hulk Hogan, TJ Dillashaw, Rafael Nadal, Jack Nicklaus, I've, it's, Paul Knoepfler, he's, It's, Mattias Bernow, we'll, Knoepfler Organizations: Service, Business, MSC, Oakland University, NFL, FDA, UFC, ESPN, CNN, UC Davis School of Medicine Locations: Bahamas, Panama

The Food and Drug Administration’s “hands-off approach” to food additives, including those found in ultraprocessed foods and energy drinks, may allow unsafe ingredients to enter the nation’s food supply, according to the authors of an editorial published Thursday. While food manufacturers can request an FDA review of new ingredients before they are added to products — and they sometimes do — they are not required to do so. From 1990 to 2010, an estimated 1,000 substances were labeled GRAS by manufacturers and were used without notifying the agency, Pomeranz said, citing earlier research. Since then, she added, there have likely been many more ingredients added to the nation’s food supply without the FDA’s oversight. “We have no idea how many substances are in the food supply based on this self-GRAS mechanism,” Pomeranz said.

Persons: ”, Jennifer Pomeranz, “, Pomeranz, ” Pomeranz, Xaq, ” Frohlich, Richard Mattes, ” Mattes, “ It’s Organizations: American, of Public Health, FDA, European Union, NYU School of Global Public Health, Auburn University, Purdue University Locations: India, Japan, GRAS, Alabama, Indiana

☆ A 68-year-old cofounded a biotech business instead of retiring. He's not getting paid for his work but values staying 'mentally engaged.'
▼ + stars: | 2024-08-08 | by ( John Towfighi | ) www.businessinsider.com time to read: +5 min

Two years ago, when he was 68, that opportunity arose: McCaman cofounded Orion Therapeutics, a small company developing new ways for RNA medicine to reach specific areas of the human body. AdvertisementMcCaman, now 70, is the vice president and chief strategy officer at Orion Therapeutics. McCaman is passionate about staying engaged with his interests and said remote work has enabled him to extend his career. McCaman and Fischer launched Orion with Deidra Mountain, a University of Tennessee professor, and Jennifer Zachry, a graduate student. Are you a baby boomer who founded a small business?

Persons: —, Michael McCaman, McCaman, It's, Davis, Intellia, Trey Fischer, Fischer, Jennifer Zachry, there's, John Deere Organizations: Service, Orion Therapeutics, Business, University of California San, University of California, Intellia Therapeutics, University of Tennessee, Orion, University of Tennessee Research Foundation, Launch Locations: Frederick , Maryland, Knoxville , Tennessee, University of California San Diego, California, Lonza, Maryland, Launch Tennessee

☆ Eli Lilly's blowout quarter should quiet investor concerns about the stock
▼ + stars: | 2024-08-08 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. The report left little doubt that Eli Lilly's best days are ahead, driven by the growth of GLP-1s. It's really early" for Zepbound, Eli Lilly CEO David Ricks said in a CNBC interview Thursday. But the good news is Eli Lilly's multibillion dollar investments to expand manufacturing capacity are paying off.

Persons: Eli Lilly, Eli Lilly's, Zepbound, Jim Cramer, Lilly, David Ricks, It's, We're, Eli Lilly hasn't, Novo, spooked Lilly, Gordon Brooks, it's, Ricks, Brooks, Verzenio, —, didn't, Jim Cramer's, Jim, George Frey Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, CNBC, Food and Drug Administration, Viking Therapeutics, Novo Nordisk —, FDA, RTP, Bloomberg, Getty Locations: Eisai, U.S, GLP, Roche, it's, Indianapolis, North Carolina, Europe, Germany, Provo , Utah

☆ Here are Tuesday's biggest analyst calls: Nvidia, Apple, Micron, Amazon, Apollo Global & more
▼ + stars: | 2024-08-06 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Tuesday's biggest calls on Wall Street: Stifel initiates GE Healthcare as buy Stifel said it's bullish on shares of the GE spin-off. Rosenblatt reiterates Nvidia as buy Rosenblatt said concerns about delays in the company's Blackwell chip are overdone. " JPMorgan downgrades Carlyle Group to neutral from overweight JPMorgan said it sees better value elsewhere. Morgan Stanley reiterates Apple as overweight Morgan Stanley said Monday's DOJ ruling on Alphabet is a negative for Apple. JPMorgan upgrades Sonic Automotive to overweight from neutral JPMorgan said investors should buy the dip in the auto company.

Persons: Stifel, it's, Morgan Stanley, Rosenblatt, Blackwell, JPMorgan, Carlyle, Piper Sandler, Piper, Palantir, KeyBanc, D.A, Davidson, Apple, GOOGL, SAH, underperform Macquarie Organizations: GE Healthcare, GE, Taiwan Semiconductor, JPMorgan, Barclays, Nvidia, Blackwell, Royal, JPMorgan downgrades Carlyle Group, Bank of America, Artificial Intelligence, Micron, Apollo, of America, Apollo Global Management, APO, Meta, Retail Media, DOJ, Apple, Aspen, Sonic Automotive, SS, UBS, Walmart, Northland, Honest, Honest Company, Macquarie, underperform Locations: Royal Caribbean, GOOGL, EVs, China

☆ Tuesday's big stock stories: What's likely to move the market in the next trading session
▼ + stars: | 2024-08-05 | by ( Jason Gewirtz | ) www.cnbc.com time to read: +2 min

It's now 18% from the February 52-week high. The stock is 17% from the April 52-week high. Dow Winners There are only four Dow stocks that are up in the last three days. Shares are 1.7% from the July 24 52-week high. The stock is 11% from the January 52-week high.

Persons: Russell, Crypto, Michael Saylor, MicroStrategy, Cleanspark, Joe Hinrichs, It's, Johnson, McDonald's Organizations: CNBC, Nasdaq, Dow Jones, Galaxy, CSX, Caterpillar, Dow, Procter, Gamble, Johnson

☆ Here are 4 things we're watching closely in the stock market this week
▼ + stars: | 2024-08-04 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

Stocks had a rough week, topped off with a pummeling Friday after the July jobs data came in weaker than expected. Until then, bad economic news was good news for the stock market, because it meant the Federal Reserve would start cutting interest rates sooner. On Thursday, a drop in U.S. manufacturing activity for July and a jump in initial jobless claims dragged down the market. Next week is light on economic data, so expect earnings reports and CEO commentaries to drive the market action. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Stocks, Dow Jones, Jim Cramer, would've, Eli Lilly, Mounjaro, Berkshire Hathaway, Krystal, Tyson, BAX, Owens, Walt, Oscar Health, CRON, Krispy, Papa, Jim Cramer's, Jim Organizations: Nasdaq, Dow, Reserve, Broadcom, Devices, Palo Alto, PMI, Wynn Resorts, Investors, Wynn, Wynn Palace, U.S . Disney, Management, and Drug Administration, Carlyle Group, Krystal Biotech, Tyson Foods, TSN, Alpha Metallurgical Resources, BioCryst Pharmaceuticals, Axsome Therapeutics, Technologies, Clover Health, Realty Income Corp, Avis Budget Group, CSX Corp, CSX, Simon Property Group, Sterling Construction Company, Teradata Corp, Yum China Holdings, ZoomInfo Technologies, Holdings, Caterpillar, Baxter International, Vulcan Materials Company, Allegheny Technologies Incorporated, Constellation Energy Group, Marathon Petroleum Corp, Owens Corning Inc, Duke Energy Corp, GXO Logistics, Brands, Builders, Wynn Resorts Ltd, WYNN, Rivian Automotive, Devon Energy Corp, GigaCloud Technology Inc, Lumen Technologies, VF Corp, Walt Disney Co, Novo Nordisk, CVS Health, Aurora Cannabis Inc, Emerson Electric Co, Sony Group Corporation, SONY, Inc, ODP Corporation, Icahn Enterprises, MannKind Corp, ACM Research, Brink's Company, AppLovin Corporation, Digital Turbine, Sarepta Therapeutics, Occidental Petroleum Corp, Bros, SolarEdge Technologies, Aspen, Coeur D'Alene Mines Corp, Co, Vistra Energy, Cheniere Energy, Cronos, Himax Technologies, Properties Trust, Papa John's, Paramount Global, Trade, Lab, B2Gold Corp, Honest Company, Gilead Sciences, Growth, Nikola Corporation, Embraer, New Fortress Energy, Construction, Jim Cramer's Charitable, CNBC, Disney, Pixar Locations: Palo, Macau, Las Vegas, Boston, Vegas, Wynn Macau, China, Novo, Coeur, Gilead

☆ Biotech and more: Hold these growth stocks for the next 10 years, the pros say
▼ + stars: | 2024-08-02 | by ( Weizhen Tan | ) www.cnbc.com time to read: +5 min

Growth stocks have been volatile, with tech names going through wild swings in recent weeks. On the whole, growth stocks are up this year, although they recently fell slightly. What are some of such stocks that investors can buy and hold for the next 10 years? CNBC Pro asked fund managers and other investors who focus on growth stocks for some ideas. There are two segments in this business: original equipment and aftermarket, according to him.

Persons: Russell, TransDigm, Casey's, Janjigian Organizations: Nasdaq, . Federal Reserve, CNBC Pro, Waste Management, Republic Services Group, Carnegie Investment, Greenwich Wealth Management, U.S . Food, Drug Administration

☆ Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market
▼ + stars: | 2024-08-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

It's Moderna's second-ever commercially available product after its Covid vaccine, which has seen demand plunge as the world emerges from the pandemic and relies less on protective shots and treatments. He added that "we've been having quite intense discussions with governments across Europe" to get Covid vaccine supply from Moderna. He is referring to the European Union's massive renegotiated Covid vaccine supply contract with Pfizer and its German partner BioNTech . Its shares are up nearly 20% this year on increasing confidence around its pipeline and messenger RNA platform, which is the technology used in its Covid vaccine and RSV shot. Moderna is also developing a stand-alone flu shot, a personalized cancer vaccine with Merck and shots for latent viruses, among other products.

Persons: It's Moderna's, Stephane Bancel, we've, Bancel, BioNTech, Moderna, I'm Organizations: Moderna Inc, Moderna, Pfizer, GSK, LSEG, Wall, Research, Merck Locations: Cambridge , Massachusetts, Europe, U.S, Moderna, Ukraine

☆ Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction
▼ + stars: | 2024-08-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company's cost cuts showed progress and sales of its breakthrough Alzheimer's drug, Leqembi, and other new products beat expectations. Leqembi, which Biogen shares with Eisai, became the second drug proven to slow the progression of Alzheimer's to win approval in the U.S. last summer. That's above the $31 million analysts had expected, according to estimates compiled by StreetAccount. Tecfidera, for example, booked $252.2 million in revenue in the second quarter, which is relatively flat from the year-earlier period. Analysts had expected the once-blockbuster drug to rake in $233.3 million in revenue for the quarter, according to StreetAccount.

Persons: Biogen, StreetAccount, Leqembi, Drug Administration greenlit Skyclarys, Biogen's Organizations: Eisai, LSEG, Reata Pharmaceuticals, Drug Administration, Sage Therapeutics Locations: U.S, Europe

☆ A new blood test can spot signs of colon cancer in your annual blood draw
▼ + stars: | 2024-07-30 | by ( ) www.businessinsider.com time to read: +3 min

The organization also estimates more than 150,000 new cases of colorectal cancer will be diagnosed this year. Colon cancer is highly treatable when caught before it spreads to other areas of the body, according to the National Cancer Institute. However, the rate of diagnoses and deaths from colon cancer has been steadily going up in people under 45, alarming doctors and researchers. AdvertisementWe don't fully understand why younger people are getting colon cancer and dying from it more frequently. Risk factors for colorectal cancer include genetics, a family history of colon cancer or colorectal polyps, and other health conditions such as inflammatory bowel disease.

Persons: —, it's, David Chung, Guardant, Chung, Colon Organizations: Service, Drug Administration, Guardant Health, Business, Harvard Medical, FDA, American Cancer Society, National Cancer Institute Locations: Colon

☆ Chart of the Day: Merck
▼ + stars: | 2024-07-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailChart of the Day: MerckMerck is down 10% today. The Investment Committee discuss the biotech sector.

Persons: Merck Merck Organizations: Merck

☆ Here are Tuesday's biggest analyst calls: Nvidia, Apple, Roblox, Netflix, Amazon, Tesla, McDonald's, Affirm & more
▼ + stars: | 2024-07-30 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Tuesday's biggest calls on Wall Street: Loop initiates BrightView as buy Loop said it's bullish on shares of the commercial landscaping company. Evercore ISI reiterates Apple as outperform Evercore said it's bullish ahead of Apple earnings later this week. " Bank of America reiterates Roblox as buy Bank of America said it's standing by Roblox ahead of earnings on August 1. Deutsche Bank reiterates McDonald's as buy Deutsche said it's standing by the fast food giant following earnings. Bank of America reiterates Goldman Sachs as buy Bank of America said top pick Goldman Sachs has "cyclical/secular tailwinds."

Persons: Evercore, it's, Jensen Huang, Nvidia's Blackwell, Blackwell, KBW, Oppenheimer, Wells, Roblox, Tesla, McDonald's, Baird, Edward Jones, Goldman Sachs, ROE resiliency, Morgan Stanley, Wells Fargo Organizations: Apple, Citi, Nvidia, " Bank of America, of America, Barclays, UBS, Amazon, Netflix, Bank of America, JPMorgan, RBC, Tesla, Deutsche Bank, Deutsche, Whirlpool, underperform Bank of America, Abbott Laboratories, Abbott Labs, Edward, Stock, 2Q, PNC, WF

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Live Nation, 3M, Uber, Eli Lilly, Amazon, Coinbase & more
▼ + stars: | 2024-07-29 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Monday's biggest calls on Wall Street: Morgan Stanley reiterates Live Nation as overweight Morgan Stanley said shares of the entertainment concert company are compelling. " Cantor Fitzgerald reiterates Nvidia as overweight Cantor said the stock is still a top pick at the firm. Guggenheim upgrades Akamai to buy from neutral Guggenheim said shares of the cloud computing networking company have more room to run. Bank of America reiterates Apple as buy Bank of America said it's bullish heading into Apple earnings later this week. JPMorgan reiterates Eli Lilly as overweight JPM said the stock is a "core holding" ahead of earnings on August 8.

Persons: Morgan Stanley, Cantor Fitzgerald, Cantor, TD Cowen, AAPL, Wells, Booz Allen Hamilton, it's, Guggenheim, Piper Sandler, Charles Schwab, Piper, Schwab, Olin, Mizuho, Bill Brown's, Myers Squibb, JPMorgan, Eli Lilly, JPM, Evercore, Tesla, Oppenheimer, Raymond James, Davidson, Raymond James downgrades Organizations: NVDA, MU, Apple, Huawei, Booz, Guggenheim, RBC, Deutsche Bank, Northrop, Deutsche, JPMorgan, Uber, Holdings, 3M, " Bank of America, Bank of America, Edge, Barclays downgrades Bristol, Myers Squibb, Barclays, Bristol, Ford, Microsoft, Charter, HSBC Locations: China, underperform

☆ Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data
▼ + stars: | 2024-07-29 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. However, in an FT interview published earlier Monday, CEO Thomas Schinecker indicated that the firm's first obesity drug could come to market "significantly faster than people are expecting," potentially by 2028. Both CT-388 and CT-996 were acquired as part of Roche's purchase of U.S. biotech company Carmot Therapeutics, which completed in January. The promising results could see Roche emerge as a potential rival to obesity drug pioneers Novo Nordisk and Eli Lilly. Schinecker told CNBC last week that he expects the company to eventually offer a suite of obesity medications.

Persons: Roche, Nordisk's Wegovy, Eli Lilly, Thomas Schinecker, Teresa Graham, Roche's, Schinecker Organizations: Nordisk's, CNBC, Roche Pharmaceuticals, Carmot Therapeutics, Novo Nordisk Locations: U.S

☆ Here are Friday's biggest analyst calls: Nvidia, Apple, Tesla, Skechers, Meta, Southwest, Amazon, Sweetgreen, & more
▼ + stars: | 2024-07-26 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Morgan Stanley reiterates Tesla as overweight Morgan Stanley said it's sticking with its overweight rating on Tesla " Tesla AI Infrastructure 'base' is by far the fastest rising part of its asset base." Morgan Stanley downgrades WW International to equal weight from overweight Morgan Stanley downgraded the company formerly known as Weight Watchers due to concerns about free-cash flow. Morgan Stanley initiates CervoMed as overweight Morgan Stanley said it's bullish on shares of the biotech company. " Morgan Stanley downgrades STMicroelectronics to equal weight from overweight Morgan Stanley downgraded the stock following earnings. Morgan Stanley reiterates Meta as overweight Morgan Stanley said buy the dip in shares of Meta.

Persons: Redburn, Lockheed Martin, Raymond James, Apple, it's, Morgan Stanley, Tesla, Piper Sandler, Alexander, Baldwin, Piper, ALEX, TD Cowen, Morgan Stanley downgrades STMicroelectronics, Baird, Meta, Guggenheim, Oppenheimer, Sweetgreen, Stifel, Jefferies, Rosenblatt Organizations: Deutsche Bank, Airlines, Deutsche, Lockheed, Apple, Citi, Amazon, AMC, International, Dianthus Therapeutics, Meta, " Bank of America, underperform Bank of America, Barclays, Microsoft, Aviation, Security, Nvidia, Qualcomm, Pharmaceuticals Locations: NYC, Brunswick

☆ Biotech is well-positioned for a Trump or Harris presidency, says Portal Innovation's John Flavin
▼ + stars: | 2024-07-26 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBiotech is well-positioned for a Trump or Harris presidency, says Portal Innovation's John FlavinJohn Flavin, Portal Innovations, joins 'Fast Money' to discuss what the upcoming election means for healthcare stocks.

Persons: Harris, John Flavin John Flavin Organizations: Biotech, Trump

☆ Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says
▼ + stars: | 2024-07-26 | by ( Weizhen Tan | ) www.cnbc.com time to read: +3 min

Weight loss drugs have drawn investor interest and shaken up other sectors in the past year or so. Novo Nordisk and Eli Lilly were two early winners of this trend, as their drugs dominate the weight loss drug market. Yuri Khodjamirian, fund manager at Tema ETFs, said both companies are a "very powerful duopoly." They're a lot more risky than the bigger ones who already have drugs on the market," Khodjamirian said. Tema ETFs offers actively managed exchange-traded funds, with a focus on health care and life sciences.

Persons: Eli Lilly, Yuri Khodjamirian, Goldman Sachs, Khodjamirian, Roche Organizations: Novo Nordisk, Tema, CNBC, Zealand Pharma, Viking Therapeutics, Tema Oncology, Mental Health Locations: Tema

☆ Viking Therapeutics stock jumps 30% after drugmaker moves weight loss injection to late-stage trial
▼ + stars: | 2024-07-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Shares of Viking Therapeutics jumped more than 30% on Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected. Viking is one of several small and large drugmakers hoping to compete in the space against Novo Nordisk and Eli Lilly , whose weight loss and diabetes GLP-1s have skyrocketed in demand over the last two years. During the call, Lian added that Viking expects to test VK2735 as a monthly injection in a future study. Viking Therapeutics' drug promotes weight loss by targeting a GLP-1 and another hormone called GIP. That pill caused 3.3% weight loss when compared to a placebo in an early-stage trial.

Persons: Eli Lilly, Viking, Brian Lian, Lian, Justin Zelin, Zelin, Eli Lilly's Zepbound Organizations: Viking Therapeutics, San, Novo Nordisk, Food and Drug Administration, FDA, Novo Nordisk's Wegovy Locations: San Diego

☆ How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot
▼ + stars: | 2024-07-24 | by ( Alistair Barr | ) www.businessinsider.com time to read: +11 min

Louis Lehot, a Silicon Valley law-firm partner, specializes in taking companies from startup to IPO. The IPO market is expected to pick up later this year, so Business Insider emailed Silicon Valley lawyer Louis Lehot, a partner at Foley & Lardner, for advice on how startups should prepare for life as public companies. Are public market investors generally keen to invest in IPOs, or are they focused elsewhere? Public market investors are selective, focusing on established profitability and sustainable growth over speculative, high-growth stories. What are the key process changes companies need to make ahead of an IPO?

Persons: Louis Lehot, Lehot, —, Lardner, Collison Organizations: Service, Foley, Healthcare, Biotech, Green Energy, Enterprise, Street, Investor

☆ Here are Wednesday's biggest analyst calls: Tesla, Spotify, Apple, GM, Alphabet, Imax, Disney & more
▼ + stars: | 2024-07-24 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Wednesday's biggest calls on Wall Street: RBC upgrades Estee Lauder to outperform from sector perform RBC said it sees an attractive risk/reward. Morgan Stanley reiterates Tesla as overweight Morgan Stanley said it's standing by shares of Tesla following the release of disappointing earnings. Morgan Stanley initiates Biohaven as overweight Morgan Stanley said it sees "value creation" for the biotech company. Morgan Stanley downgrades General Motors to equal weight from overweight Morgan Stanley said it sees a more "balanced" risk/reward for shares of GM. " Cantor Fitzgerald downgrades Tesla to neutral from overweight Cantor downgraded Tesla following earnings on Tuesday.

Persons: Lauder, Raymond James, Taylor Morrison, it's, Morgan Stanley, Tesla, Tesla's, TD Cowen, JFrog, Cowen, Lockheed Martin, Goldman Sachs, Goldman, Smith, Stifel, GOOGL, Jefferies downgrades, Gamble, Jefferies, Piper Sandler downgrades Ulta, Piper, Gordon Haskett, Joel Anderson, Cantor Fitzgerald downgrades Tesla, Cantor Organizations: RBC, Taylor Morrison Homes, Tesla, Lockheed, Spotify, JPMorgan, Garden Entertainment, Apple JPMorgan, Apple, Jefferies downgrades Colgate, Palmolive, Procter, Colgate, Gamble, Deutsche Bank, Deutsche, Motors, GM, Barclays, Disney, Universal Studios, Davidson Locations: GenAI, Malibu

☆ We're raising our price target on Danaher stock as it sheds a major overhang
▼ + stars: | 2024-07-23 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

That improvement in the bioprocessing end market is super important because it has been a huge overhang for Danaher shares, and the life sciences space in general. We were concerned about the bioprocessing market after rival Sartorius cut its guidance last week. The management team has effectively navigated the bioprocessing slowdown better than others and kept expectations managed — a big reason we've stuck by the stock during a difficult few quarters. Based on these strong results and the improving bioprocessing market, we are raising our price target to $295 from $280 and reiterating our 1 rating. All three operating segments are expected to post sales decline rates in the low single digits.

Persons: Sartorius, Rainer Blair, Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: Club, Revenue, LSEG, Management, Diagnostics, Leica, Beckman Coulter Diagnostics, Cepheid, CNBC, Getty Locations: bioprocessing, Danaher, U.S, Europe, China, Bioprocessing

Search resuls for: "biotech"

25 mentions found